- Home
- ALNY vs PSA Comparison
ALNY vs PSA Comparison
Compare ALNY & PSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- PSA
- Stock Information
- Founded
- ALNY 2002
- PSA 1972
- Country
- ALNY United States
- PSA United States
- Employees
- ALNY N/A
- PSA N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- PSA Real Estate Investment Trusts
- Sector
- ALNY Health Care
- PSA Real Estate
- Exchange
- ALNY Nasdaq
- PSA Nasdaq
- Market Cap
- ALNY 59.2B
- PSA 51.9B
- IPO Year
- ALNY 2004
- PSA N/A
- Fundamental
- Price
- ALNY $459.28
- PSA $292.38
- Analyst Decision
- ALNY Strong Buy
- PSA Buy
- Analyst Count
- ALNY 27
- PSA 12
- Target Price
- ALNY $420.73
- PSA $330.33
- AVG Volume (30 Days)
- ALNY 1.1M
- PSA 641.0K
- Earning Date
- ALNY 10-30-2025
- PSA 10-29-2025
- Dividend Yield
- ALNY N/A
- PSA 4.07%
- EPS Growth
- ALNY N/A
- PSA N/A
- EPS
- ALNY N/A
- PSA 9.17
- Revenue
- ALNY $2,461,963,000.00
- PSA $4,758,111,000.00
- Revenue This Year
- ALNY $58.97
- PSA $1.58
- Revenue Next Year
- ALNY $38.81
- PSA $3.74
- P/E Ratio
- ALNY N/A
- PSA $32.14
- Revenue Growth
- ALNY 5.01
- PSA 2.13
- 52 Week Low
- ALNY $205.87
- PSA $256.60
- 52 Week High
- ALNY $469.81
- PSA $369.99
- Technical
- Relative Strength Index (RSI)
- ALNY 70.91
- PSA 54.38
- Support Level
- ALNY $444.66
- PSA $291.70
- Resistance Level
- ALNY $458.30
- PSA $299.25
- Average True Range (ATR)
- ALNY 10.97
- PSA 4.18
- MACD
- ALNY -3.77
- PSA 0.70
- Stochastic Oscillator
- ALNY 71.78
- PSA 57.14
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About PSA Public Storage
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,300 self-storage facilities in 40 states and approximately 245 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.